STERIS plc

STERIS plc (NASDAQ: STER) operates as a leading global provider of products and services that support patient care with an emphasis on infection prevention. The company helps customers create a healthier and safer world by offering an innovative mix of consumable products, services, and capital equipment across healthcare and life science markets worldwide. STERIS's website is located at www.steris-ir.com.

The company operates through three reportable business segments. The Healthcare segment provides comprehensive offerings for healthcare providers worldwide, focused on sterile processing departments and procedural centers such as operating rooms and endoscopy suites. This segment offers infection prevention consumables, capital equipment including sterilizers and surgical tables, equipment maintenance services, and outsourced instrument reprocessing. The Applied Sterilization Technologies segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, along with integrated sterilization equipment and control systems. The Life Sciences segment provides products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing, including pharmaceutical detergents, sterilizers, washers, and vaporized hydrogen peroxide systems.

STERIS maintains an average workforce of approximately 18,000 employees distributed across its segments, with less than twelve percent represented by work councils or labor unions. The company operates manufacturing and service facilities across multiple continents, serving customers throughout the Americas, Europe, and Asia. As of March 31, 2026, STERIS held 606 United States patents and 2,402 patents in other jurisdictions, along with approximately 2,079 trademark registrations worldwide.

The company's intellectual property portfolio and continuous improvement initiatives form core competitive advantages. STERIS maintains a quality management system designed to achieve quality from incoming materials through manufacturing and distribution. The company previously operated a Dental segment, which was divested in fiscal 2025. STERIS competes with numerous large companies possessing significant product portfolios and global reach, as well as smaller competitors with limited offerings. The company's backlog of unfilled capital equipment purchase orders totaled $490.7 million as of March 31, 2026.